Novel synergistic combination therapy in fibrolamellar carcinoma

Timeframe: 2022 – 2023 Goal: Knock-out gene targets in a mouse model of FLC to identify potentially effective drug combinations for patients with advanced FLC Principal Investigator: Sean Ronnekleiv-Kelly, MD, Surgical Oncology This study will apply an innovative gene-editing based technology (genome-wide CRISPR knockout screen) on a mouse cellular model to screen all possible cancer …

Read more

Role of the innate immune system in fibrolamellar hepatocellular carcinoma (FL-HCC) using zebrafish as a model system

Timeframe: 2016 – 2019 Goal: Use zebrafish as a model system for fibrolamellar carcinoma to study the immune system Principal Investigator: Sofia de Oliveira, Ph.D., EMBO Postdoctoral Fellow, Huttenlocher Immunology Lab Few FLC animal models currently exist limiting our ability to study FLC in the context of a complete organism. While cell-based models are extremely …

Read more

A gene editing approach to develop new and effective models for FLC

Timeframe: 2021 Goal: Generate a mouse model of FLC Principal Investigator: Sean Ronnekleiv-Kelly, MD, Surgical Oncology The purpose of this study was to generate a robust pre-clinical murine model of FLC that can provide a basis for understanding factors contributing to FLC formation, and for therapeutic development. The study proposed to develop a mouse model …

Read more